文献速递艾滋病与性传播感染

肯尼亚南裂谷与基苏木儿童及青少年HIV病毒载量抑制与耐药相关因素分析

Prevalence and Correlates of Viral Load Suppression and Human Immunodeficiency Virus (HIV) Drug Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya.
PubMed 文献 · Clin Infect Dis · 2022-01-01

2018至2020年在肯尼亚南裂谷与基苏木开展横断面研究,纳入969名1至19岁接受抗逆转录病毒治疗超过6个月的儿童及青少年HIV感染者,病毒抑制率为0.80(95%CI 0.78-0.83),病毒未抑制者中119例(81.5%)检出主要耐药突变。

要点

  • 病毒抑制率为0.80(95%CI 0.78-0.83)。
  • 病毒未抑制者中81.5%(119例)检出主要HIV耐药突变。
  • ART超过24个月、含整合酶抑制剂方案和三级卫生机构就诊与病毒抑制正相关。

核心结论

  • HIV治疗项目应针对有治疗失败风险的儿科患者(即照护者病毒抑制失败及依从性困难者)开展干预。

研究设计与样本

  • 2018至2020年在肯尼亚开展的横断面研究,纳入969名1至19岁、接受ART超过6个月的儿童及青少年HIV感染者。
  • 参与者接受病毒载量检测,病毒载量≥1000拷贝/mL者接受HIV耐药突变检测,并完成社会人口学问卷和病历摘录。

主要发现

  • 病毒抑制(病毒载量<1000拷贝/mL)率为0.80(95%CI 0.78-0.83)。
  • ART超过24个月(调整PR 1.22;95%CI 1.06-1.41)、含整合酶链转移抑制剂方案(1.13;1.02-1.26)和三级卫生机构就诊(1.23;1.11-1.36)与病毒抑制正相关。
  • 过去一个月漏服ART≥3次(调整PR 0.73;95%CI 0.58-0.92)、母亲病毒血症(0.72;0.53-0.98)与病毒抑制负相关。
  • 与<2次依从性咨询转介相比,3-7次(0.90;0.83-0.97)、8-13次(0.89;0.82-0.97)和≥14次(0.84;0.77-0.92)依从性咨询转介与病毒抑制负相关。
  • 病毒未抑制者中119例(81.5%)检出任何主要HIV耐药突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children and adolescents living with HIV (CALHIV) face unique challenges, including poorer treatment outcomes, risk for drug-resistance mutations (HIVDRMs), and limited drug formulations. We estimated viral suppression (VS) prevalence and evaluated predictors of VS and HIVDRMs in Kenya. METHODS: From 2018-2020, CALHIV 1-19 years on antiretroviral therapy (ART) >6 months were enrolled in this cross-sectional study. Participants underwent viral load (VL) testing; those with VL ≥1000 copies/mL had HIVDRM testing. Sociodemographic questionnaires and medical record abstraction were completed. VS prevalence (VL <1000 copies/mL) was estimated; robust Poisson regression models were used to estimate prevalence ratios (PRs) and 95% CIs for associations between potential predictors of VS. RESULTS: Nine hundred and sixty-nine participants were enrolled. VS prevalence was .80 (95% CI: .78-.83). Being on ART >24 months (adjusted PR [aPR]: 1.22; 95% CI: 1.06-1.41), an integrase strand transfer inhibitor-containing regimen (1.13; 1.02-1.26), and attending a level 3 health facility (1.23; 1.11-1.36) were associated with VS. Missing ≥3 doses of ART in the past month (aPR: .73; 95% CI: .58-.92), having a viremic mother with HIV (.72; .53-.98), and having 3-7 (.90; .83-.97), 8-13 (.89; .82-.97), or ≥14 (.84; .77-.92) compared with <2 adherence counseling referrals were inversely associated with VS. A high proportion (n = 119, 81.5%) of unsuppressed participants had evidence of any major HIVDRM. CONCLUSIONS: HIV treatment programs should target interventions for pediatric patients at risk for treatment failure-namely, those with a caregiver with failed VS and those struggling with adherence.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tsikhutsu I, Bii M, Dear N, et al. Prevalence and Correlates of Viral Load Suppression and Human Immunodeficiency Virus (HIV) Drug Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya. Clin Infect Dis. 2022. PMID: 35092424. doi:10.1093/cid/ciac059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。